Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: Pooled data from six clinical trials

BMJ Open Respiratory Research

Volumn 6, Issue 1, 2019, Pages

  Lancaster, Lisa ^a   Crestani, Bruno ^b   Hernandez, Paul ^c   Inoue, Yoshikazu ^d   Wachtlin, Daniel ^e   Loaiza, Lazaro ^e   Quaresma, Manuel ^e   Stowasser, Susanne ^e   Richeldi, Luca ^f  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b BICHAT HOSPITAL   (France)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

interstitial fibrosis

Indexed keywords

CARBON MONOXIDE; NINTEDANIB; PLACEBO;

ADULT; ARTICLE; BLEEDING; BREATHING RATE; CARDIOVASCULAR SYMPTOM; DIARRHEA; DISEASE EXACERBATION; EPISTAXIS; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEMOPTYSIS; HUMAN; HYPERTRANSAMINASEMIA; LIFE EXPECTANCY; LONG TERM SURVIVAL; LUNG CAPACITY; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SMOKING; SURVIVAL; SURVIVAL TIME;

EID: 85063504918     PISSN: None     EISSN: 20524439     Source Type: Journal    
DOI: 10.1136/bmjresp-2018-000397     Document Type: Article

References (26)

1. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018;198:e44-68.
2. Kreuter M, Swigris J, Pittrow D, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res 2017;18.
3. Fernández Pérez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010;137:129-37.
4. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011;140:221-9.
5. Raghu G, Chen S-Y, Yeh W-S, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014;2:566-72.
6. Guenther A, Krauss E, Tello S, et al. The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respir Res 2018;19.
7. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-87.
8. Richeldi L, Kreuter M, Selman M, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the tomorrow trial and its open-label extension. Thorax 2018;73:581-3.
9. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82.
10. Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med 2019;7:60-8.
11. Lancaster L, Ilowite J, Trampisch M, et al. Effect of nintedanib on disease progression: results from a phase IIIB trial in patients with idiopathic pulmonary fibrosis. Nashville, TN, USA: Poster presented at the Pulmonary Fibrosis Foundation, 2017.
12. Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med 2016;113:74-9.
13. Collett D. Modelling survival data in medical research. London: Chapman and Hall, 1994.
14. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 1982;73:883-8.
15. Bowen JM. Mechanisms of TKi-induced diarrhea in cancer patients. Curr Opin Support Palliat Care 2013;7:162-7.
16. Boehringer Ingelheim Pharmaceuticals, Inc. OFEV® (nintedanib) prescribing information, 2018. Available: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Ofev/ofev.pdf [Accessed 30 Nov 2018].
17. Bendstrup E, Wuyts W, Alfaro T, et al. Nintedanib in idiopathic pulmonary fibrosis: practical management recommendations for potential adverse events. Respiration 2019;97:173-84.
18. Maher TM, Inoue Y, Case AH, et al. Effect of dose reductions and/or interruptions on the efficacy of nintedanib in patients with idiopathic pulmonary fibrosis (IPF): Subgroup analysis of the INPULSIS trials. Washington, DC, USA: Poster presented at the American Thoracic Society International Conference, 2017.
19. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009;6:465-77.
20. Corte T, Bonella F, Crestani B, et al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res 2015;16.
21. Noth I, Oelberg D, Kaul M, et al. Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA. Eur Respir J 2018;52. doi: 10.1183/13993003.02106-2017. [Epub ahead of print: 27 Jul 2018].
22. Collard HR, Ward AJ, Lanes S, et al. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 2012;15:829-35.
23. Fisher M, Nathan SD, Hill C, et al. Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. J Manag Care Spec Pharm 2017;23(3-b Suppl):S17-S24.
24. HE J, Glaspole I, Grainge C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian idiopathic pulmonary fibrosis registry. Eur Respir J 2017;49.
25. Rinciog C, Watkins M, Chang S, et al. A cost-effectiveness analysis of nintedanib in idiopathic pulmonary fibrosis in the UK. Pharmacoeconomics 2017;35:479-91.
26. Vašáková M. Real world idiopathic pulmonary fibrosis in the Empire registry. Poster presented at the European Respiratory Society International Congress, 2018.